Modified Polymyxin Derivatives Reduce Nephrotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymyxin derivatives used to treat Gram-negative bacterial infections often exhibit nephrotoxicity and variable efficacy, limiting their therapeutic potential against multidrug-resistant strains.
Innovation Solution
Development of polymyxin compounds with specific N-terminal modifications, including amino functionality and nitrogen-containing heterocycles, which reduce toxicity and enhance antimicrobial activity against Gram-negative bacteria, including strains resistant to Polymyxin B and Colistin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If polymyxin derivatives with reduced positive charges are used to decrease nephrotoxicity, then renal toxicity is reduced, but antibacterial activity may be compromised
Solution Approach 1:
The patent modifies the chemical structure of polymyxin derivatives by changing the number and positioning of positive charges (quaternary ammonium groups) to reduce nephrotoxicity while maintaining antibacterial activity. Specifically, compounds with two quaternary ammonium groups at defined positions in the fatty acyl chain were synthesized and evaluated, demonstrating reduced renal toxicity compared to traditional polymyxins with more positive charges.
Solution Approach 2:
The invention creates composite molecular structures by combining modified fatty acyl chains with the polymyxin peptide backbone. This composite approach allows optimization of both toxicity and activity properties through careful selection of fatty acid components and their attachment to the peptide structure.
2Object-affected harmful factors
If polymyxin derivatives with modified structures are developed to reduce toxicity, then safety is improved, but consistency of activity across different pathogens may be reduced
Solution Approach 1:
The patent develops polymyxin derivatives with broad-spectrum activity against multiple Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. The modified compounds maintain consistent antibacterial activity across these diverse pathogens while reducing toxicity, achieving universal effectiveness against MDR Gram-negative bacteria.
3Reliability
If traditional polymyxins are used to treat MDR Gram-negative infections, then therapeutic effect is achieved, but neurotoxicity and nephrotoxicity occur
Solution Approach 1:
The patent extracts and modifies specific components of the polymyxin molecule (the fatty acyl chain with positive charges) that are responsible for toxicity while preserving the core peptide structure that provides antibacterial activity. By removing or reducing excess positive charges in the fatty acyl portion, the invention separates toxic from therapeutic functions.
Solution Approach 2:
The invention converts the harmful excessive positive charges in traditional polymyxins into a beneficial reduced charge configuration. The modified derivatives retain sufficient positive charge for effective interaction with bacterial membranes while having reduced affinity for mammalian kidney tissue, thus converting a harmful property into a selectively beneficial one.
Data Source
AI summary
Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R8, —RA, Q, —R16, —R17 are as described in further detail in the description.